Promising Phase 1 Results for New Monoclonal Antibody to PCSK9
Promising results from very early studies with an experimental new cholesterol-lowering drug, a monoclonal antibody to PCSK9, have been published in the New England Journal of Medicine. Evan Stein and...
View ArticlePCSK9 Inhibitor Enhances Cholesterol-Lowering Effect of Atorvastatin
When added to low-dose atorvastatin, a much-discussed new monoclonal antibody to PCSK9 significantly lowers cholesterol more effectively than atorvastatin alone, according to a phase 2 study published...
View ArticleSelections from Richard Lehman’s Literature Review: December 10th
CardioExchange is pleased to reprint selections from Dr. Richard Lehman’s weekly journal review blog at BMJ.com. Selected summaries are relevant to our audience, but we encourage members to engage with...
View ArticlePreliminary Outcomes Results For PCSK9 Inhibitor
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first...
View ArticleSelections from Richard Lehman’s Literature Review: October 6th
CardioExchange is pleased to reprint this selection from Dr. Richard Lehman’s weekly journal review blog at BMJ.com. Selected summaries are relevant to our audience, but we encourage members to engage...
View ArticleMore Information Emerges About the PCSK9 Inhibitors
New information emerged today about two new cholesterol-lowering drugs that have been attracting a lot of attention. Data about the PCSK9 inhibitors — evolocumab, under development by Amgen, and...
View ArticleMore Preliminary Signs That PCSK9 Inhibitors May Improve Outcomes
A new analysis of available data from early trials with PCSK9 inhibitors adds to the growing evidence showing that this much-anticipated new class of drugs dramatically lowers LDL cholesterol and...
View Article
